Data as of Q4 2025 (Dec 31, 2025)

VR Adviser, LLC

โ€ขCIK: 1615982โ€ขFiling: Q4 2025

**VR Adviser, LLC** manages $2.0B across a concentrated portfolio of 27 positions. The fund exhibits significant conviction in its top holdings, notably maintaining a substantial position in APGE at $641.1M. Further allocations include ORKA ($125.7M), VRDN ($120.8M), and SYRE ($120.7M), indicating a focused, high-conviction investment mandate. This structure suggests a deep-dive approach targeting specific market opportunities within its selected sectors.

Total AUM
$2.0B
QoQ Performance
+13.9%
Positions
27
Top 10 Concentration
73.7%
Latest Filing
Q4 2025

Top Holdings Allocation

APGE
ORKA
VRDN
SYRE
KALV
APGE31.7%
ORKA6.2%
VRDN6.0%
SYRE6.0%
KALV5.4%
OCUL4.4%
YB4P4.1%
COGT3.5%

๐Ÿ“ˆ Biggest Buys

SYRE
SPYRE THERAPEUTICS INC
+37.2%
6.0% of portfolio
HELP
CYBIN INC
NEW
1.6% of portfolio
VOR
VOR BIOPHARMA INC
+288.8%
1.3% of portfolio
MAZE
MAZE THERAPEUTICS INC
+25.8%
3.2% of portfolio
โ€”
CRESCENT BIOPHARMA INC.
+53.7%
1.2% of portfolio

๐Ÿ“‰ Biggest Sells

COGT
COGENT BIOSCIENCES INC
-50.0%
3.5% of portfolio
OCUL
OCULAR THERAPEUTIX INC
-44.4%
4.4% of portfolio
ORIC
ORIC PHARMACEUTICALS INC
-14.0%
2.3% of portfolio
ENGN
ENGENE HOLDINGS INC
-5.4%
2.1% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

โ€”
METSERA INC
SOLD
$196.3M
CDTX
CIDARA THERAPEUTICS INC
SOLD
$90.7M
ABVX
ABIVAX SA
SOLD
$49.0M
CATBUSD
ASTRIA THERAPEUTICS INC
SOLD
$17.9M
โ€”
PHARVARIS N V
SOLD
$16.8M
+2 more exited positions

Changes from Q3 2025

NEW1 new position
โ†‘7 increased
โ†“4 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023